Business Context and Reporting Period
Company: Butterfly Network, Inc. (BFLY)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Butterfly Network is a digital health company developing portable, semiconductor-based ultrasound technology ("Ultrasound-on-Chip"). The company sells handheld ultrasound devices (Butterfly iQ+ and iQ3), software subscriptions, and educational services to healthcare systems, providers, and veterinarians globally. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $82.1 | $65.9 | +24.5% |
| Product Revenue | $54.2 | $40.0 | +35.4% |
| Software & Services Revenue | $27.9 | $25.9 | +7.7% |
| Gross Profit | $48.8 | $16.9 | +189.7% |
| Gross Margin | 59.5% | 25.6% | +33.9 pts |
| Net Loss | $(72.5) | $(133.7) | -45.8% (Improvement) |
| Operating Loss | $(74.4) | $(145.6) | -48.9% (Improvement) |
| Cash & Equivalents (End of Period) | $88.8 | $134.4 | $(45.6) |
| Accumulated Deficit | $(802.1) | $(729.6) | N/A |
Liquidity & Debt: The company had no long-term debt as of December 31, 2024. Cash and cash equivalents totaled $88.8 million. The company utilized $41.7 million in net cash for operating activities in 2024, a significant improvement from the $98.8 million burn in 2023.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 24.5% year-over-year, driven primarily by a 35.4% increase in product revenue. This was fueled by the launch of the next-generation Butterfly iQ3 probe and higher volume across U.S. sales channels.
- Margin Expansion: Gross margin improved significantly from 25.6% to 59.5%. This was largely due to the non-recurrence of a $21.1 million inventory write-down recorded in 2023. Excluding this one-time charge, product revenue costs increased in 2024 due to higher sales volume.
- Expense Reduction: Operating expenses decreased by $39.2 million (24.1%) compared to 2023.
- R&D: Decreased 32.0% to $37.8 million, driven by personnel cost reductions and business transformation initiatives.
- General & Administrative: Decreased 19.8% to $39.8 million, due to lower personnel and professional service costs.
- Other Expenses: Decreased 77.6% to $4.1 million, reflecting lower severance and legal costs compared to the prior year.
- Units Fulfilled: Increased by 19.0% (3,131 units) compared to 2023.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Management has reduced annual cash requirements by approximately $180 million since 2022, bringing them to less than $50 million annually.
- The company is shifting focus toward enterprise software solutions and large healthcare system deployments to improve revenue mix and profitability over time.
- Butterfly iQ3 has demonstrated strong uptake since its February 2024 release.
- The company initiated a pilot program for virtual chronic care management services in January 2025.
Recent Capital Raise: On January 31, 2025, the company completed a public offering of 27.6 million shares of Class A common stock, generating gross proceeds of $86.9 million (net proceeds approx. $81.0 million).
Risks & Contingencies:
- Profitability: The company has incurred losses since inception and anticipates continuing to incur significant losses for at least the next several years.
- Supply Chain: Reliance on single suppliers for critical components (TSMC for chips, Benchmark for assembly) poses supply disruption risks.
- Legal: The company is subject to a securities class action lawsuit and stockholder derivative actions regarding the 2021 Business Combination.
- Regulatory: Subject to extensive FDA and international regulations; failure to maintain compliance could restrict sales.
- Intellectual Property: Reliance on licensed technology from Stanford University; loss of rights could prevent product sales.
Investor Verification Checklist
- Cash Runway: Verify the impact of the $81.0 million net proceeds from the January 2025 offering on the company's liquidity and operational runway.
- Inventory Valuation: Confirm that the 2023 $21.1 million inventory write-down was a non-recurring event and assess current inventory levels ($70.8 million) against sales forecasts.
- Software Mix: Monitor the "Software and other services mix" (33.9% in 2024), which decreased from 39.2% in 2023, to ensure the strategic shift toward recurring revenue is on track.
- Legal Exposure: Review the status of the pending securities class action and derivative lawsuits for potential settlement costs or judgments.
- Supplier Concentration: Assess the risks associated with the single-source agreements with TSMC and Benchmark Electronics, particularly regarding geopolitical stability in Taiwan.